Limb-girdle muscular dystrophies (LGMD) are a family of hereditary muscle diseases 42 that are inherited in an autosomal recessive or dominant manner [1]. Most recessively 43 inherited LGMDs are postulated to be caused by a loss-of-function mechanism, 44 because the protein is absent in patient muscle tissue and many mutations lead to 45 premature stops or frameshifts. However, the mechanisms of dominantly inherited 46
Abstract (200 words): 24
Dominant mutations in the HSP70 co-chaperone DNAJB6 cause a late onset muscle 25 disease termed limb girdle muscular dystrophy type 1D (LGMD1D), which is 26 characterized by protein aggregation and vacuolar myopathology. Disease mutations 27 reside within the G/F domain of DNAJB6, but the molecular mechanisms underlying 28 dysfunction are not well understood. Using yeast, cell culture, and mouse models of 29
LGMD1D, we find that the toxicity associated with disease-associated DNAJB6 requires 30 its interaction with HSP70, and that abrogating this interaction genetically or with small 31 molecules is protective. In skeletal muscle, DNAJB6 localizes to the Z-disc with HSP70. 32
Whereas HSP70 normally diffuses rapidly between the Z-disc and sarcoplasm, the rate 33 of HSP70's diffusion in LGMD1D mouse muscle is diminished likely because it has an 34 unusual affinity for the Z-disc and mutant DNAJB6. Treating LGMD1D mice with a 35 small molecule inhibitor of the DNAJ-HSP70 complex re-mobilizes HSP70, improves 36 strength and corrects myopathology. These data support a model in which LGMD1D 37 mutations in DNAJB6 are a gain-of-function disease that is, counter-intuitively, mediated 38 via HSP70 binding. Thus, therapeutic approaches targeting HSP70:DNAJB6 may be 39 effective in treating this inherited muscular dystrophy. 40 87 Yeast has been a powerful model system used to understand the mechanisms of DNAJ 88 proteins, owing to their high conservation. The G/F domain of DNAJB6 is homologous 89 to the specific yeast DNAJ protein, Sis1 [15] . This is convenient because, unlike 90 DNAJB6, there are known substrates for Sis1, and the deletion of Sis1 results in strong 91 phenotypes. For example, Sis1 is required for cell viability and is essential for yeast 92 prion propagation [15] . Thus, studying the impact of human LGMD1D mutations in the 93 yeast Sis1 model allows one to form hypotheses about how they might impact DNAJB6 94 function. Indeed, we previously expressed a chimeric Sis1-DNAJB6, in which Sis1's 95 G/F domain was replaced with that of DNAJB6 [15] . The yeast expressing the Sis1-G/F 96 chimera were viable and supported prion propagation, consistent with the homology 97 between these proteins. However, when an LGMD1D missense mutation within the G/F 98 domain was introduced, prion propagation was impaired, suggesting a partial loss-of-99 function [15] . This effect on prion propagation appears to be conserved, because 100
DNAJB6b also facilitates the disaggregation of proteins with prion-like, low complexity 101 sequences, such as huntingtin and TDP-43, in mammalian cells [15, 16] . Moreover, 102
LGMD1D mutations in DNAJB6 impair this function [15] . Together, these observations 103 suggested to us that the Sis1 yeast model might be used to probe the mechanism of 104
LGMD1D mutations. 105 106 Here, we use yeast, mammalian cells, and a new mouse model, combined with 107 chemical probes targeting chaperones, to reveal an unexpected relationship between 108 DNAJB6 mutations and aberrant cycling of HSP70 at the Z-disc. Counter-intuitively, we 109 6 find that inhibiting the interaction of DNAJB6 with HSP70, either genetically or 110 pharmacologically, can partially restore HSP70 mobility and rescue muscle phenotypes 111 in treated mice. These results suggest new ways of potentially treating LGMD1D. More 112 broadly, they provide insight into the mechanisms of myopathy-associated 113 chaperonopathies. 114
Results: 115
To model LGMD1D mutant dysfunction, we generated homologous DNAJB6 disease-116 associated mutations in Sis1. We found that yeast expressing Sis1-F106L and Sis1-117 F115I (corresponding to DNAJB6-F93L and F100I) had reduced viability ( Figure 1A) . 118
This was similar to previous reports demonstrating that deletion of the Sis1 G/F domain 119 dominantly affects yeast viability in the setting of endogenous Sis1 [17] . This dominant 120 effect can be rescued by a second cis mutation within the C-terminus, L268P, which 121 was shown to abrogate Ssa1/Hsp70 interaction with Sis1 [18] . Similarly, we found that 122 combining the L268P mutation with Sis1-F106L or F115I, restored yeast viability ( Figure  123 1A). Notably, generating a second mutation in Sis1-F115I that impairs Sis1 124 dimerization, ΔDD, did not rescue viability ( Figure 1A) . These data indicate that the 125 gain of LGMD1D mutant toxicity occurs via the DNAJ-HSP70 interaction and not DNAJ 126 dimerization. Importantly, we confirmed that these effects were not due to a 127 destabilization of Sis1 ( Figure 1B) . 128
129
One feature of LGMD1D muscle pathology is the formation of inclusions composed of 130 association in HeLa cells (Figure 2A -C). While LGMD1D mutant DNAJB6b expression 138 increased the number of TDP-43 positive stress granules post heat shock, the addition 139 of the H31Q mutation resulted in TDP-43 granules that appeared similar to DNAJB6b-140 WT expression ( Figure 2A-B ). We further tested whether the H31Q mutation 141 ameliorated TDP-43 insolubility, as TDP-43 stress granules become detergent insoluble 142 in the presence of LGMD1D mutant DNAJB6b [15] . In order evaluate TDP-43 143 aggregation, we subjected lysates to differential extraction and centrifugation generating 144 a total lysate fraction (T), a soluble supernatant fraction (S) and an insoluble pelleted 145 fraction (P). Similar to what was observed with fluorescence microscopy, there was an 146 increase in insoluble/pelleted (P) TDP-43 following heat shock in cells expressing 147
LGMD1D mutant DNAJB6b as compared to DNAJB6b-WT expression. However, when 148 an H31Q mutation was present with the disease mutation, the increase in pelleted TDP-149 43 was reduced ( Figure 2C ). In combination with our yeast model, these data provide 150 additional support that the DNAJB6-HSP70 interaction plays a critical role in LGMD1D 151
pathogenesis. 152 153
To dissect how the H31Q mutation modulates DNAJB6 function, we specifically 154 examined the binding of DNAJB6 and HSP70. As expected based on previous results 155
[19], the H31Q mutation decreased the binding of DNAJB6b-WT to co-expressed Flag-156 HSP70 ( Figure 3A) . Notably, LGMD1D mutant DNAJB6b had increased association 157 with Flag-HSP70 and this interaction was weakened by a secondary H31Q mutation 158 ( Figure 3A ). Abrogating the HSP70 interaction in LGMD1D mutant DNAJB6b with the 159 H31Q mutation also corrected other gain-of-function effects, such as an increase in 160
LGMD1D mutant DNAJB6b stability ( Figure 3B -C), and heat shock associated cell 161 death ( Figure 3D ). These data suggest that the gain-of-function effect of LGMD1D 162 mutant DNAJB6b can be partially corrected by inhibiting the DNAJB6:HSP70 163 interaction. 164
165
Based on these results, we wanted to further explore whether HSP70 might be a 166 therapeutic target in LGMD1D. Specifically, we wondered whether inhibiting the 167 association of HSP70 with DNAJB6b with small molecules might partially protect 168 against LGMD1D phenotypes in mammalian disease models. As a proof-of-concept, 169
we tested four different compounds known to modulate HSP70 interactions with co-170 chaperones [20] . YM-01, JG98 and JG231 inhibit HSP70 activity by interfering with its 171 interactions with co-chaperones, including DNAJ proteins [21] . Conversely, SW02 172 activates HSP70 by enhancing its interaction with DNAJ proteins [22] . At 12h post-173 transfection with DNAJB6b and TDP-43, HeLa cells were treated for 16 hours with 174 vehicle, or an HSP70 modulator prior to heat shock. By quantifying the percentage of 175 cells with TDP-43 granules ( Figure 3E ), we found that SW02 increased the gain-of-176 function effect of LGMD1D mutant DNAJB6b, whereas YM-01, JG98 and JG231 177 reduced TDP-43 inclusions, specifically in LGMD1D mutant DNAJB6b expressing cells. 178
These effects seemed to be dependent upon the HSP70 interaction, because there was 179 no change when the HSP70 modulators were applied in the setting of LGMD1D mutant 180
DNAJB6b harboring an additional H31Q mutation ( Figure 3E ). 181 182
We have previously described a mouse model that overexpresses V5-tagged 183
DNAJB6b-F93L using an MCK promoter in skeletal muscle [12] . These mice had 184 premature death, weakness, myopathic muscle and protein inclusions similar to that 185 seen in LGMD1D patients, and displayed these phenotypes as early as two months of 186 age [12] . To generate a model of LGMD1D that did not rely on overexpression, we 187 generated the DNAJB6-F90I mutation (homologous to the F89I mutation in humans) in 188 mice using CRISPR/Cas9. Heterozygous DNAJB6-F90I mice developed progressive 189 weakness, muscle atrophy and scattered fibers with myofibrillar disorganization after 12 190 months of age ( Figure 4A -F). Consistent with the phenotypes seen in the transgenic 191 mouse model, immunoblot analysis showed an increase in both DNAJB6a and 192
DNAJB6b isoforms, as well as desmin ( Figure 4G ). In addition, several chaperone 193 proteins were increased, as assessed by qPCR ( Figure 4H we hypothesized that this process might be damaged by LGMD1D mutations. To test 205 this idea, we evaluated the localization of DNAJB6b and HSP70 in live mouse muscle 206 by imaging the flexor digitorum brevis (FDB) following electroporation of GFP-tagged 207 DNAJB6b or HSP70. As expected, DNAJB6b-WT localized to the Z-disc, while HSP70 208 localized to the Z-disc and, to varying degrees, the M-line ( Figure S1A ). Localizations 209 were confirmed via second harmonic generation imaging, which identifies the A bands 210 and by expression of desmin-GFP with mCherry-DNAJB6b-WT ( Figure S1A -B). To 211 understand chaperone dynamics at the Z-disc, we performed fluorescence recovery 212 after photobleaching (FRAP) of DNAJB6b and HSP70. Fluorescence from DNAJB6b-213
WT was rapidly recovered at the Z-disc ( Figure 5A -B), indicating that most of the protein 214 is mobile ( Figure 5C ) and transiently associates with Z-disc clients. By contrast, two 215 different LGMD1D mutations (F89I and P96R) in DNAJB6b showed slower recovery at 216 the Z-disc ( Figure 5A-B) . 217 218
Using this system, we next wanted to test whether the slow recovery of DNAJB6b-F89I 219 might also affect HSP70 in a dominant manner. To test this concept, we performed a 220 similar FRAP experiment using 3 month old DNAJB6-F90I knockin mice that express 221 one copy of the DNAJB6-F90I (F89I in humans) at endogenous levels. Three months 222 was chosen as the time point because, at this early age, the mice do not show any 223 obvious muscle pathology. Whereas HSP70 had rapid fluorescence recovery in 224 littermate control mice, its recovery was slowed in DNAJB6-F90I knockin mice ( week ( Figure 6A-B ), and at 4 and 8 weeks, these mice also had an increase in isolated 240 muscle mass ( Figure 7A -B). To further assess the effect of JG231 treatment, we 241 quantitated myofiber size and degree of myofibrillar disarray in DNAJB6b-WT or 242
DNAJB6b-F93L mice treated with or without JG231 following treatment at 4 and 8 243 weeks ( Figure 7C -E). Myofibrillar disarray was quantitated using an NADH stain and 244 scored from 0-6 in a blinded fashion by two neuromuscular physicians with muscle 245 pathology expertise (AF and CW). Examples of scored images are in Figure S3 . 246
Notably, there was a significant shift toward larger myofibers and a decrease in the 247 percentage of fibers with abnormal internal architecture, as demonstrated on NADH 248 staining at both 4 and 8 weeks ( Figure 7E ). 249 250 JG231 treatment had a modest effect on the expression of other chaperone proteins, as 251 evaluated by qPCR of tibialis anterior muscle ( Figure 7F ), suggesting that this effect 252 was independent of a global stress response. To determine if there were changes in 253 other proteins found to accumulate in LGMD1D muscle, we immunoblotted for TDP-43, 254 SQSTM1, HSP70 and desmin ( Figure 7G ). Strikingly, after 8 weeks of treatment with 255 JG231, there was a significant decrease in total desmin protein levels ( Figure 7G ), as 256 might be expected for a partial recovery of quality control. The observed decrease in 257 desmin accumulation also matches the improvement in internal, muscle architecture 258 that were seen in the treated mice. Together, these results suggest that the DNAJB6-259 HSP70 interaction is an unexpected drug target for LGMD1D. 260
Discussion: 261
Protein chaperones are important for the maintenance of sarcomeric structure and 262 muscle function [7] . Dominant mutations in DNAJB6 cause LGMD1D, a myopathy with 263 myofibrillar disorganization and protein inclusions [3, 4] . Our data supports an 264 unexpected mechanism in which the dominant effect of mutations in DNAJB6's G/F 265 domain require its interaction of HSP70. Specifically, yeast expressing homologous 266
LGMD1D mutations in Sis1 have reduced viability, but this toxicity is corrected by 267 including a second mutation that abrogates binding to HSP70. Moreover, genetically 268 blocking the interaction DNAJB6 with HSP70 rescues the dominant effect of LGMD1D 269 mutations on TDP-43 disaggregation and post-heat shock toxicity. There are a number 270 of possible mechanisms to link these observations. For example, the interactions of 271 mutant DNAJB6 with HSP70 might reduce the stability of DNAJB6 clients. HSP70 has 272 been shown to prevent proper folding if it is not allowed to cycle off client [24] . Indeed, 273 although HSP70 is often associated with its roles in protein folding, its prolonged 274 binding appears to be antagonistic to this process in many settings {Sekhar, 2012 275 #305}. Alternatively, the prolonged interaction of mutant DNAJBb with HSP70 might 276 titrate it away from other clients, leading to broader disruption of HSP70-dependent 277 processes [25] . These mechanisms are not mutually exclusive, and both could result in 278 a more general impairment of protein quality control. 279 280 Several lines of evidence suggest that Z-disc proteins, such as desmin, may be 281 DNAJB6b clients. For example, loss of DNAJB6 in myoblasts leads to the accumulation 282 of desmin [14] . We found that normal DNAJB6b and HSP70 transiently localize to the 283 Z-disc in mouse muscle, as measured by FRAP. However, in mice expressing an 284
LGMD1D mutation, the movement of HSP70 on the Z disc is slowed, suggesting that it 285 is more avidly associated with mutant DNAJB6. Strikingly, treatment with small 286 molecules known to interrupt DNAJ and HSP70 interactions [21] partially recovered 287 HSP70 kinetics. These results further substantiate the idea that the phenotypes 288 associated with LGMD1D mutant DNAJB6 require HSP70 interactions. 289 290 Moreover, a recent study exploring the pathogenic mechanism of mutations in BAG3 291 associated with another chaperonopathy showed striking similarities [26] . Dominant 292 mutations in BAG3 lead to its destabilization and subsequent aggregation [27] . Mutant 293 BAG3 aggregates contain additional chaperones, including HSP70 and DNAJB6. 294
Likewise, blocking the interaction of HSP70 with BAG3 can partially rescue phenotypes, 295
suggesting that BAG3-associated myopathy is, like LGMD1D, due to a dominant 296 interaction with HSP70. The similarities between these findings suggest that 297 myopathies might share a common molecular feature of aberrant protein quality control, 298 leading to a "traffic jam" of chaperones on Z-disc proteins. Re-mobilizing these 299 chaperones might be a generalizable approach to partially restore muscle function in 300 myopathies. 301 302 More immediately, this study suggests that the HSP70-DNAJB6 interaction could be a 303 drug target for the treatment of LGMD1D. However, while HSP70 inhibitors have been 304 studied in preclinical safety studies in mice [28, 29] , any treatment for human myopathy 305 would require long-term administration and the safety of chronic treatment is not yet 306 clear. The key to translation of this concept might be in creating more selective 307 inhibitors, that act exclusively on the DNAJB6-HSP70 interaction. The inhibitors 308 currently available, while useful chemical probes for proof-of-concept studies, have 309 broad effects on HSP70 co-chaperone contacts. Thus, a selective inhibitor of mutant 310 DNAJB6-HSP70 interactions may be the (safest and) most effective. 311
Methods: 312
Yeast Studies: 313
The yeast strains used in this study are derived from Saccharomyces cerevisiae 74-314 Medium containing 1mg/mL 5-fluoroorotic acid (5-FOA) that select against cells 322 maintaining URA3-marked plasmids was used to replace WT Sis1 with the mutant 323 constructs using the plasmid shuffle technique. Plasmid transformations were done 324 using PEG/LioAC technique and the cells were selected using SD-trp plates. Plasmids 325 pRS316-SIS1 and pRS314-sis1-L268P were received as gifts from Dr. E. Craig [17] . 326
Construction of pRS314-SIS1 was described earlier [15] . Using pRS314-SIS1 as 327 template, mutations in SIS1 were generated using bridge PCR with the indicated 328 oligonucleotides: sis1-F106L 329 (5'GATTCTCCGGAGGACATGCGCTCAGTAATGAGGATGC and 330 5'GCATCCTCATTACTGAGCGCATGTCCTCCGGAGAATC), sis1-F115I 331 (5'GATGCTTTCAATATTATTTCACAATTCTTTGGC and 332 5'GCCAAAGAATTGTGAAATAATATTGAAAGCATC). Using pRS314-sis1-F106L and 333
pRS314-sis1-F115I as templates, double mutations with sis1-L268P were generated 334 using (5'GTTTCTCTAGTTATCCATCTG and 5'GTTTCTCTAGTTATCCATCTG) primer 335 pair. pRS414GPD-sis1-∆DD-F115I was created by using 336 (5'ATACTAGTATGGTCAAGGAGACAAAAC and 337 5'CGCATCGATTTATGGATAGTCCACTTTATATTTTAC) primers, followed by digestion 338
with SpeI/ClaI, and ligation with pRS314GPD that was digested with the same 339 enzymes. Yeast cells were spotted as described previously [31] . Briefly, yeast cells 340 grown overnight were pelleted, washed and normalized with water to an optical density Muscle tissues and cultured cells were homogenized using RIPA lysis buffer (50 mM 387
Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate and 1 mM EDTA) 388 supplemented with protease inhibitor cocktail (Sigma-Aldrich), and lysates were 389 centrifuged at 13 000 rpm for 10 min. Protein concentrations were determined using a 390
BCA protein assay kit (Thermo Fisher Scientific). Aliquots of lysates were solubilized in 391
Laemmli sample buffer and equal amounts of proteins were separated on 12% SDS-392 PAGE gels. Proteins were transferred to nitrocellulose membrane and then blocked with 393 5% nonfat dry milk in PBS with 0.1% Tween-20 for 1 h. The membrane was then 394 incubated with primary antibodies, specific to the protein of interest, in 5% nonfat dry 395 milk in PBS with 0.1% Tween overnight at 4°C. After incubation with the appropriate 396 secondary antibody conjugated with horseradish peroxidase, enhanced 397 chemiluminescence (GH Healthcare, UK) was used for protein detection. Immunoblots 398
were obtained using the G:Box Chemi XT4, Genesys Version 1.1.2.0 (Syngene). 
In vivo Electroporation 472
Mice are anesthetized using 2.5% isoflurane. We will be injecting the FDB (flexor 473 digitalis brevis). The foot pad is wiped with ethanol and 10uL of hyaluronidase at a 474 concentration of 2mg/mL is injected into the FDB from the base of the pad towards the 475 digits. The mouse then is monitored in a recovery cage for 1-2hrs. Again, the animal is 476 anesthetized with 2.5% isoflurane and the foot pad wiped with ethanol. The plasmid is 477 then injected with endotoxin free plasmid diluted in sterile PBS to a volume of 50uL into 478 Isolated muscle was mounted using tragacanth gum (Sigma, G1128) and quick frozen 505 in liquid nitrogen-cooled 2-methylbutane. Samples were stored at −80°C until sectioning 506 into 10-µm sections. Hematoxylin and eosin (H&E), nicotinamide adenine dinucleotide 507 diaphorase (NADH), and Laminin staining was performed as previously described [12] . 508
Sections were blocked in PNB (PerkinElmer), incubated with primary antibody followed 509 by the appropriate secondary antibody. Briefly, muscle sections were affixed to slides 510 incubated for 10 min in ice-cold acetone, mounted with Mowiol 4-88 (sigma) + DAPI 511 and examined using a fluorescence microscope (Nikon 80i upright+ and Roper 512
Scientific EZ monochrome CCD camera with deconvolution software analysis [NIS 513
Elements, Nikon]). Non-fluorescent images were taken with a 5 megapixel color CCD 514 (Nikon). Image processing and analysis were done with (NIS Elements 4.0) software 515 and Adobe Photoshop. Fluorescent Images of random fields were taken with a ×20 516 objective using a Nikon Eclipse 80i fluorescence microscope. 517 518 Fluorescence Recovery After Photobleaching (FRAP) and Second harmonic generation: 519
The mice were treated as follow: YM01 was diluted in DMSO to 24 mg/mL to mimic 520 conditions used in cell culture. 10µL of YM01 or vehicle was injected into the mouse 521 footpad 24-48 hours prior to imaging. JG2321 was diluted in DMSO to 8 mg/mL to 522 mimic conditions used in cell culture. 50µL of JG231or vehicle was injected 523 intraperitoneally every other day for 2 weeks prior to imaging. For imaging, Mice were 524 anesthetized with isoflurane with 5% used for induction and 1-1.5% for maintenance 525 during surgery at the level of reflex suppression. Skin overlying the FDB was removed. 526
Mice were mounted on a customized viewing pane to facilitate imaging with the inverted 527 two photon microscope. Electroporated skeletal muscle in live mice was observed with 528 a Zeiss LSM 880 Airyscan confocal microscope with a motorized inverted Zeiss Axio 529
Observer Z1 microscope frame. We used a 40X 1.2 NA water immersion objective, an 530 excitation wavelength of 950 nm and an emission filter of 499-571 nm for GFP probes. 531
Regions of interest (2.4µM x 8.49µM) were bleached with the Zeiss software. Laser 532 settings were adjusted depending on myofiber depth to achieve at least 60% reduction 533 in GFP signal in myofibers with variable tissue depths. This was achieved with an 534 excitation wavelength of 950nm at 2-10% laser power for 2-5 iterations at 0.24µs 535 duration. One image was captured immediately before and after photobleaching, 536 followed by a series of post bleach images every 1 -2 seconds, depending on the 537 experiment. FRAP experiments for each condition used at least 3 different myofibers 538 per animal. Each myofiber was tested at 3 different locations along its length. A single 539 excitation wavelength at 800 nm was used for 2-photon electron microscopy (2PEM) 540 and recorded using a 40x 1.2 NA water immersion objective. Second harmonic 541 generation was detected with a non-descanned-detector through a bandpass filter of 542 380-430 nm. As described previously, second harmonic generation occurs mostly 543 from 2PEM of non-centrosymetric structures, and is restricted to collagen fibers and 544 striated muscle myosin rod domains [33] . Data were analyzed using ImageJ. We transformed with plasmids over-expressing Sis1-WT, Sis1-F106L (DNAJB6-F93L homologous), Sis1-F115I (DNAJB6-F100I homologous) constructs, an empty vector control (EV) or Sis1 mutant constructs with a second mutation that impairs HSP70 association (L268P) or blocks Sis1 dimerization (ΔDD). Cultures were normalized and serially diluted five-fold and were spotted on medium (SD-trp) to select for the plasmid or medium (YPD) that provides no selection. B) Western blot analysis from lysates of yeast expressing the Sis1 constructs in B. Pgk1 is a loading control. Images for both (A) and (B) are representative of three independent experiments.
Figure 2:
LGMD1D mutations in DNAJB6b impair TDP-43 disaggregation which is corrected with a second H31Q mutation. A-C) Hela cells were co-transfected with mCherry-TDP-43 and wild-type or LGMD1D mutant (F89I, F93L, P96R or F100I) GFP-DNAJB6b. In some cases a second mutation in the J domain (H31Q) was also present. Transfected cells were heat shocked at 42º for one hour prior to analysis. A) Quantification of the percentage of transfected cells with TDP-43 aggregates. The comparison between groups was performed using a paired Student t-test **P < 0.005, ***P < 0.0005, ****P < 0.00005. B) Representative fluorescent images of mCherry-TDP-43 positive nuclei quantified in (A). C) Lysates from cells in (A) were separated into total (T), soluble (S), and pellet (P) fractions and then subjected to SDS-PAGE and Western blot using an α-TDP43 and α-GAPDH antibodies.
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C. LGMD1D mutant dysfunction is corrected by abrogating HSP70 interaction. A) Hela cells were co-transfected with plasmids expressing Flag-Hsp70 and wild-type or LGMD1D mutant (F89I, F93L, P96R or F100I) GFP-DNAJB6b. In some cases a second mutation in the J domain (H31Q) was also present. 24 hours later, cells were lysed and GFP-DNAJB6 was immunoprecipitated and subsequently immunoblotted for GFP or Flag. B) Tetracycline inducible isogenic 293 cell lines expressing (WT, H31Q, F93L, F93L-H31Q, P96R or P96R-H31Q) V5-DNAJB6b were induced with tetracycline for 24h and then removed for the indicated times. Lysates were immunoblotted for V5 and GAPDH. C) Quantitation of V5-DNAJB6b from three independent experiments. comparison between groups was performed using a paired Student t-test. * P≤ 0.05, **P < 0.005 and ***P < 0.0005. D) Hela cells were transfected with the indicated constructs, subjected to heat shock at 42º for 1 hour and the percentage of ethidium homodimer-1-positive cells was quantitated. Data are presented as percent cells found positive/dead. Comparison between groups was performed using a paired Student t-test **P < 0.005, ***P < 0.0005. E) Hela cells were co-transfected with mCherry-TDP-43 and wild-type or LGMD1D mutant (F89I, F93L, P96R or F100I) GFP-DNAJB6b. In some cases a second mutation in the J domain (H31Q) was also present. After 12h of transfection, cells were treated for 16h with either YM-01, JG231, JG98 (Hsp70 inhibitors) or SW02 (Hsp70 activator). The percentage of cells with TDP-43 positive nuclear aggregates granules was quantified following 1h of heat shock. The comparison between groups was performed using a paired Student t-test *P < 0.05, **P < 0.005, ***P < 0.0005.
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Figure 5:
Imaging of DNAJB6 and HSP70 kinetics at the Z-disc. A) Fluorescence recovery after photobleaching was performed with two-photon microscopy on mouse foot pad following electroporation into the FDB with constructs expressing GFP-DNAJB6b-WT, -P96R, or -F89I. Representative images show baseline prior to bleaching (pre), immediately post-bleach (t=0s), and following (2s or 56s) of recovery (t=2s or t=56s). B) Graph of the normalized RFI vs time in seconds for the studies in (A). D) Graph of the percentage of maximum fluorescence recovery corresponding to the mobile vs immobile fraction. D-I) Experiments similar to (A) following electroporation of HSP70-GFP in C57 control or DNAJB6-F90I heterozygous mice. In some cases, mouse footpad was injected with YM01 (D-F) or mice were given i.p. injections of JG231 (G-I). D and G) Representative images show baseline prior to bleaching (pre), immediately post-bleach (t=0s), and following 10s of recovery (t=10s). E and H) Graph of the normalized RFI vs time in seconds for the studies in (D and G respectively). F and I) Graph of the percentage of maximum fluorescence recovery corresponding to the mobile vs immobile fraction for the studies in (D and G respectively). 
